Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Background: Increasing evdence supports the suggestion that the immune cell infiltration (ICI) patterns play a pivotal role in tumor progression in breast cancer (BRCA). Nonetheless, there has been no comprehensive analysis of the ICI patterns effects on the clinical outcomes and immunotherapy. Methods: Multiomic data for BRCA samples were downloaded from TCGA. ESTIMATE algorithm, ssGSEA method, and CIBERSORT analysis were used to uncover the landscape of the tumor immune microenvironment (TIME). BRCA subtypes based on the ICI pattern were identified by consensus clustering and principal-component analysis was performed to obtain the ICI scores to quantify the ICI patterns in individual tumors. Their prognostic value was validated by the Kaplan-Meier survival curves. Gene set enrichment analysis (GSEA) was applied for functional annotation. Immunophenoscore (IPS) was employed to explore the immunotherapeutic role of the ICI scores. Finally, the mutation data was analyzed by using the “maftools” R package. Results: Three different immune infiltration patterns with a distinct prognosis and biological signature were recognized among 1,198 BRCA samples. The characteristics of TIME under these three patterns were highly consistent with three known immune profiles: immune- excluded, immune-desert, and immune-inflamed phenotypes, respectively. The identification of the ICI patterns within individual tumors based on the ICI score, developed under the ICI-related signature genes, contributed into dissecting biological processes, clinical outcome, immune cells infiltration, immunotherapeutic effect, and genetic variation. High ICI score subtype, characterized with a suppression of immunity, suggested an immune-exhausted phenotype. Abundant effective immune cells were discovered in the low ICI score patients, which corresponded to an immune-activated phenotype and might present an immunotherapeutic advantage. Immunophenoscore was implemented as a surrogate of immunotherapeutic outcome, low-ICI scores samples obtained a significantly higher immunophenoscore. Enrichment of the JAK/STAT and VEGF signal pathways were activated in the ICI low-score subgroup. Finally, the synergistic effect between the ICI score and the tumor mutation burden (TMB) was confirmed. Conclusion: This work comprehensively elucidated that the ICI patterns served as an indispensable player in complexity and diversity of TIME. Quantitative identification of the ICI patterns in individual tumor will contribute into mapping the landscape of TIME further optimizing precision immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 4,935
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Stanton, S. E., & Disis, M. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0165-6 · Cited by 828
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807
Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.-T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 746
George, S., Miao, D., Demetri, G. D., Adeegbe, D., Rodig, S. J., Shukla, S., Lipschitz, M., Amin-Mansour, A., Raut, C. P., Carter, S. L., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.001 · Cited by 483
Kim, J. E., Patel, M. A., Mangraviti, A., Kim, E. S., Theodros, D., Velarde, E., Liu, A., Sankey, E. W., Tam, A., Xu, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1535 · Cited by 461
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Goodman, A., Patel, S. P., & Kurzrock, R. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.168 · Cited by 461
IDO1 in cancer: a Gemini of immune checkpoints
Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 437
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
Silva-Santos, B., Mensurado, S., & Coffelt, S. B. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0153-5 · Cited by 425
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Lipson, E. J., Forde, P. M., Hammers, H.-J., Emens, L. A., Taube, J. M., & Topalian, S. L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.013 · Cited by 306
Tissue-resident memory T cells in breast cancer control and immunotherapy responses
Byrne, A., Savas, P., Sant, S., Li, R., Virassamy, B., Luen, S. J., Beavis, P. A., Mackay, L. K., Neeson, P. J., & Loi, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0333-y · Cited by 301
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
Koren, S., & Bentires-Alj, M. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.031 · Cited by 284
Chen, Y.-P., Wang, Y.-Q., Lv, J.-W., Li, Y.-Q., Chua, M. L. K., Le, Q.-T., Lee, N., Colevas, A. D., Seiwert, T., Hayes, D. N., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy470 · Cited by 275
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Duffy, M. J., Synnott, N. C., & Crown, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4753-7 · Cited by 235
Causes of death after breast cancer diagnosis: A US population‐based analysis
Afifi, A. M., Saad, A. M., Al‐Husseini, M. J., Elmehrath, A. O., Northfelt, D. W., & Sonbol, M. B. (2020) · Cancer · doi:10.1002/cncr.32648 · Cited by 210
Panagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 191
Baxevanis, C. N., Fortis, S. P., & Perez, S. A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.018 · Cited by 172
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Emens, L. A. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.147 · Cited by 172
Immune targeting in breast cancer.
Cimino‐Mathews, A., Foote, J. B., & Emens, L. A. (2015) · PubMed · Cited by 162
Hypertension: Focus on autoimmunity and oxidative stress
Small, H. Y., Migliarino, S., Cześnikiewicz‐Guzik, M., & Guzik, T. J. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.05.085 · Cited by 150
Schwartzentruber, D. J., Topalian, S. L., Mancini, M., & Rosenberg, S. A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.10.3674 · Cited by 139
Tuaillon, É., Valéa, D., Becquart, P., Tabaa, Y. A., Méda, N., Bolloré, K., de Perre, P. V., & Vendrell, J.-P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803107 · Cited by 133
Dumas, A., Vaz Luis, I., Bovagnet, T., El Mouhebb, M., Di Meglio, A., Pinto, S., Charles, C., Dauchy, S., Delaloge, S., Arveux, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01726 · Cited by 131
Xue, Z., Vis, D. J., Bruna, A., Sustic, T., van Wageningen, S., Batra, A. S., Rueda, O. M., Bosdriesz, E., Caldas, C., Wessels, L. F. A., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0044-4 · Cited by 125
Breast cancer prognosis signature: linking risk stratification to disease subtypes
Yu, F., Quan, F., Xu, J., Zhang, Y., Xie, Y., Zhang, J., Lan, Y., Yuan, H., Zhang, H., Cheng, S., et al. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby073 · Cited by 120
Schwartzentruber, D. J., Solomon, D., Rosenberg, S. A., & Topalian, S. L. (1992) · Journal of Immunotherapy · doi:10.1097/00002371-199207000-00001 · Cited by 86
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Aktaş, B. Y., Taban, H., & Aksoy, S. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1900150 · Cited by 68
FOXP3 inhibits angiogenesis by downregulating VEGF in breast cancer
Li, X., Gao, Y., Li, J., Zhang, K., Han, J., Li, W., Hao, Q., Zhang, W., Wang, S., Zeng, C., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0790-8 · Cited by 64
Harao, M., Forget, M., Roszik, J., Gao, H., Babiera, G. V., Krishnamurthy, S., Chacon, J. A., Li, S., Mittendorf, E. A., DeSnyder, S. M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0364 · Cited by 64
Hwang, M. L., Lukens, J. R., & Bullock, T. N. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5829 · Cited by 40
Johansson, A., Palli, D., Masala, G., Grioni, S., Agnoli, C., Tumino, R., Giurdanella, M. C., Fasanelli, F., Sacerdote, C., Panico, S., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0664-7 · Cited by 36
Cytotoxic CD4+ T Cells in Bladder Cancer—A New License to Kill
Sacher, A. G., Paul, M. S., Paige, C. J., & Ohashi, P. S. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.013 · Cited by 32
Novel Isatin-based activator of p53 transcriptional functions in tumor cells.
Mirgayazova, R., Khadiullina, R., Mingaleeva, R. N., Chasov, V. V., Gomzikova, M. O., Garanina, E. E., Rizvanov, A. A., & Bulatov, E. (2019) · PubMed Central · doi:10.22099/mbrc.2019.34179.1419 · Cited by 22
Wen, Y., Wei, Y., Zhang, S., Li, S., Liu, H., Wang, F., Zhao, Y., Zhang, D., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw028 · Cited by 22
A genomic copy number signature predicts radiation exposure in post‐ C hernobyl breast cancer
Wilke, C., Braselmann, H., Heß, J., Klymenko, S. V., Chumak, V. V., Захарцева, Л. М., Bakhanova, E. V., Walch, A. K., Selmansberger, M., Samaga, D., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31533 · Cited by 16
Tanaka, H., Watanabe, M., Zeniya, M., & Takahashi, H. (1991) · Acta Pathologica Japonica · doi:10.1111/j.1440-1827.1991.tb02504.x · Cited by 4
Cited by
Zheng, X., Wang, Y., & Qiu, X. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176840 · Cited by 10
Metadata
- Authors
- Xu, Q., Chen, S., Hu, Y., & Huang, W.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-08-27
- Volume
- 12
- Pages
- 711433-711433
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3196745241
- Cited by
- 180
- References
- 58
- FWCI
- 11.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.